肿瘤相关抗原及抗体在肝癌诊断中的研究进展

王戊辰; 周永宁

doi:10.3969/j.issn.1001-5256.2014.06.025

肿瘤相关抗原及抗体在肝癌诊断中的研究进展

DOI: 10.3969/j.issn.1001-5256.2014.06.025

兰州大学第一医院消化内科

详细信息

中图分类号: R735.7
计量
- 文章访问数: 2841
- HTML全文浏览量: 14
- PDF下载量: 576
- 被引次数: 0
出版历程
- 收稿日期: 2013-06-29
- 出版日期: 2014-06-20

Research progress in tumor- associated antigen antibodies for diagnosis of liver cancer

Department of Gastroenterology, The First Affiliated Hospital of Lanzhou University

摘要

摘要: 肝癌是全世界最常见的恶性肿瘤之一,虽然其治疗手段不断进步,但病死率仍居高不下。早期诊断可提高患者的生存时间,因此,亟须探索新的生物标志物以便及时诊断肝癌。当前研究的热点集中于肿瘤相关抗原（TAA）及对应的自身抗体来作为肿瘤血清学生物学标志,介绍了自身抗体的产生过程以及当前在肝癌组织中所发现的TAA组和抗-TAAs。此外,指出了这些新发现的自身抗体具有较高敏感性和特异性,将有助于肝癌的早期诊断。
- 肝肿瘤 /
- 抗原,肿瘤 /
- 自身抗体 /
- 综述
Abstract: Liver cancer is one of the most common malignant tumors in the world. The mortality of patients with liver cancer remains high even with increasing progress in therapies. Early diagnosis is helpful for prolonging the survival of patients, so new biomarkers need to be explored for timely diagnosis and treatment of liver cancer. The present research focuses on tumor- associated antigens ( TAAs) and their corresponding autoantibodies as serological biomarkers of liver cancer. The production of autoantibodies and the TAAs and anti- TAAs currently found in the liver cancer tissue are summarized. In addition, it is pointed out that these newly found autoantibodies have relatively high sensitivity and specificity for the early diagnosis of liver cancer.
- liver neoplasms /
- antigens, neoplasm /
- autoantibodies /
- review

HTML全文

参考文献(34)

[1] JEMAL A, BRAY F, CENTER MM, et al.Global cancer statistics[J].CA Cancer J Clin, 2011, 61 (2) :69-90.

[2]YANG BH, ZHANG BH.Risk factors and prevention for primary liver cancer[J].J Clin Hepatol, 2012, 28 (4) :253-258. (in Chinese) 杨秉辉, 张博恒.重视肝癌的病因和预防[J].临床肝胆病杂志, 2012, 28 (4) :253-258.

[3]MORALES M, CABRERA MA, MAESO MD, et al.Use of panitumumab in the treatment of acinar cell carcinoma of the pancreas:a case report[J].Oncol Lett, 2013, 5 (3) :969-971.

[4]FINN OJ.Immune response as a biomarker for cancer detection and a lot more[J].N Engl J Med, 2005, 353 (12) :1288-1290.

[5]LI J, WANG LJ, YING X, et al.Immunodiagnostic value of combined detection of autoantibodies to tumor-associated antigens as biomarkers in pancreatic cancer[J].Scand J Immunol, 2012, 75 (3) :342-349.

[6]BALDWIN RW.Immunity to transplanted tumour:the effect of tumour extracts on the growth of homo-logous tumours in rats[J].Br J Cancer, 1955, 9 (4) :646-651.

[7]BELOUSOV PV, KUPRASH DV, NEDOSPASOV SA, et al.Autoantibodies to tumor-associated antigens as cancer biomarkers[J].Curr Mol Med, 2010, 10 (2) :115-122.

[8]LOILOME W, YOOYUEN S, NAMWAT N, et al.PRKAR1A overexpression is associated with increased ECPKA autoantibody in liver fluke-associated cholangio carcinoma:application for assessment of the risk group[J].Tumour Biol, 2012, 33 (6) :2289-2298.

[9]SPIOTTO MT, RETH MA, SCHREIBER H.Genetic changes occurring in established tumors rapidly stimulate new antibody responses[J].Proc Natl Acad Sci U S A, 2003, 100 (9) :5425-5430.

[10]CASIANO CA, MEDIAVILLA-VARELA M, TAN EM.Tumor-associated antigen arrays for the serological diagnosis of cancer[J].Mol Cell Proteomics, 2006, 5 (10) :1745-1759.

[11]ANDERSON KS, LABAER J.The sentinel within:exploiting the immune system for cancer biomarkers[J].J Proteome Res, 2005, 4 (4) :1123-1133.

[12]BEI R, MASUELLI L, PALUMBO C, et al.A common repertoire of autoantibodies is shared by cancer and autoimmune disease patients:inflammation in their induction and impact on tumor growth[J].Cancer Lett, 2009, 281 (1) :8-23.

[13]LUNA CORONELL JA, SYED P, SERGELEN K, et al.The current status of cance biomarker research using tumour-associated antigens for minimal invasive and earlycancer diagnostics[J].J Proteomics, 2012, 76:102-115.

[14]SUZUKI A, IIZUKA A, KOMIYAMA M, et al.Identification of melanoma antigens using a Serological Proteome Approach (SERPA) [J].Cancer Genomics Proteomics, 2010, 7 (1) :17-23.

[15] BABEL I, BARDE RAS R, DIAZ-URIARTE R, et al.Identification of tumor-associated autoantigens for the diagnosis of colorectal cancer in serum using high density protein microarrays[J].Mol Cell Proteomics, 2009, 8 (10) :2382-2395.

[16]KOBAYASHI S, KIM SR, IMOTO S, et al.Histopathological diagnosis of early HCC through biopsy:efficacy of victoria blue and cytokeratin 7 staining[J].Dig Dis, 2012, 30 (6) :574-579.

[17]NIE RH, LIU YY.Application of detection of tumor markers AFP, CA125, CA199 and CEA in diagnosis and treatment for patients with hepatitis and liver cirrhosis[J].J Jilin Univ:Med Edit, 2012, 38 (1) :119-122. (in Chinese) 聂荣慧, 刘元元.肿瘤标志物AFP、CA125、CA199和CEA检测在肝炎、肝硬化患者诊断和治疗中的应用[J].吉林大学学报:医学版, 2012, 38 (1) :119-122.

[18]ZHANG WP.Alpha-fetoprotein and liver cancer:a new understanding of an old problem[J].J Med Res, 2013, 42 (6) :3-5. (in Chinese) 章卫平.甲胎蛋白与肝癌:老问题的新认识[J].医学研究杂志, 2013, 42 (6) :3-5.

[19] ERTLE JM, HEIDER D, WICHERT M, et al.A Combination ofα-fetoprotein and des-γ-carboxy prothrombin is superior in detection of hepatocellular carcinoma[J].Digestion, 2013, 87 (2) :121-131.

[20]MATSUBARA M, SHIRAHA H, KATAOKA J, et al.Des-γ-carboxyl prothrombin is associated with tumor angiogenesis in hepatocellular carcinoma[J].J Gastroenterol Hepatol, 2012, 27 (10) :1602-1608.

[21]CHOI JY, JUNG SW, KIM HY, et al.Diagnostic value of AFP-L3and PIVKA-II in hepatocellular carcinoma according to total-AFP[J].World J Gastroenterol, 2013, 19 (3) :339-346.

[22]YANG Y, XIA T, LI N, et al.Combined effects of p53 and MDM2polymorphisms on susceptibility and surgical prognosis in hepatitis B virus-related hepatocellular carcinoma[J].Protein Cell, 2013, 4 (1) :71-81.

[23]LU M, NAKAMURA RM, DENT ED, et al.Aberrant expression of fetal RNA-binding protein p62 in liver cancer and liver cirrhosis[J].Am J Pathol, 2001, 159 (3) :945-953.

[24]TAKASHIMA M, KURAMITSUY, YOKOYAMAY, et al.Proteomic analysis of autoantibodies in patients with hepatocellular carcinoma[J].Proteomics, 2006, 6 (13) :3894-3900.

[25]STENNER-LIEWEN F, LUO G, SAHIN U, et al.Definition of tumor-associated antigens in hepatocellular carcinoma[J].Cancer Epidemiol Biomarkers Prev, 2000, 9 (3) :285-290.

[26]UEMURA M, NOUSO K, KOBAYASHI Y, et al.Identification of the antigens predominantly reacted with serum from patients with hepatocellular carcinoma[J].Cancer, 2003, 97 (10) :2474-2479.

[27]LI L, CHEN SH, YU CH, et al.Identification of hepatocellularcarcinoma-associate dantigens and autoantibodies by serological proteome analysis combined with protein microarray[J].J Proteome Res, 2005, 7 (2) :611-620.

[28]ZOU L, WU Y, PEI L, et al.Identification of leukemia-associated antigens in chronic myeloid leukemia by proteomic analysis[J].Leuk Res, 2005, 29 (12) :1387-1391.

[29]CHEN Y, ZHOU Y, QIU S, et al.Autoantibodies to tumor-associated antigens combined with abnormal alpha-fetoprotein enhance immunodiagnosis of hepatocellular carcinoma[J].Cancer Lett, 2010, 289 (1) :32-39.

[30]LI Y, WANG K, DAI L, et al.HapMap-based study of CIP2A gene polymorphisms and HCC susceptibility[J].Oncol Lett, 2012, 4 (2) :358-364.

[31]SHAO Q, REN P, LI Y, et al.Autoantibodies against glucoseregulated protein 78 as serological diagnostic biomarkers in hepatocellular carcinoma[J].Int J Oncol, 2012, 41 (3) :1061-1067.

[32]AKADA J, KAMEI S, ITO A, et al.A new type of protein chip to detect hepatocellular carcinoma-related autoimmune antibodies in the sera of hepatitis C virus-positive patients[J].Proteome Sci, 2013, 11 (1) :33.

[33]NAHON P, SUTTON A, RUFAT P, et al.Myeloperoxidase and superoxide dismutase 2 polymorphisms comodulate the risk of hepatocellular carcinoma and death in alcoholic cirrhosis[J].Hepatology, 2009, 50 (5) :1484-1493.

[34]TAN Y, QIN S, HOU X, et al.Proteomic-based analysis for identification of proteins involved in 5-fluorouracil resistance in hepatocellular carcinoma[J].Curr Pharm Des, 2014, 20 (1) :81-87.

施引文献

资源附件(0)

访问统计